The U.S. gastrointestinal endoscopic device market was valued at almost $1.7 billion in 2011. iData’s recent report found that increases in colon cancer screening and anti-reflux procedures as well as the adoption of newer technologies such as double-balloon endoscopes and ultrasound endoscopes will drive the market to reach a value of over $2.7 billion by 2018. Anti-reflux procedures, used for the treatment of gastroesophageal reflux disease (GERD), will increase almost seven fold by 2018 in the United States, driving anti-reflux device sales. This increase will be fueled by the obesity epidemic in the U.S., improved awareness among patient and physicians as well as recent studies that indicated serious side effects from long-term use of anti-reflux medication, the primary alternative to surgery. EndoGastric Solutions is currently the only company offering an anti-reflux device, however, two new companies are currently in the process of gaining FDA approval.
For more information, read more about the gastrointestinal endoscopic device market here.